

filed 2-22-08

PTO/SB/08a (05-07)

Approved for use through 09/30/2007. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10775699
	Filing Date		2004-02-10
	First Named Inventor	David Bebbington	
	Art Unit	1624	
	Examiner Name	Tamthom Ngo Truong	
	Attorney Docket Number	VPI/00-130-07 DIV US	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1	6653301	B2	2003-11-25	Vertex Pharmaceuticals Incorporated <i>Bebbington et. al.</i>		
	2	6989385	B2	2006-01-24	Vertex Pharmaceuticals Incorporated <i>Bebbington et. al.</i>		
	3	6664247	B2	2003-12-16	Bebbington et al.		
	4	6653300	B2	2003-11-25	Bebbington et al.		
	5	7087603	B2	2006-08-08	Bebbington et al.		
	6	6656939	B2	2003-12-02	Bebbington et al.		
	7	3755322		1973-08-28	Ciba-Geigy Corporation <i>Winter et. al.</i>		
	8	6841579	B1	2005-01-11	Sugen, Inc.		

/Tamthom Truong/

02/08/2008

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VPI/00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

9	3133081		1964-05-12	Smith Line & French Laboratories <i>Lafferty et. al.</i>	
10	3935183		1976-01-27	Imperial Chemical Industries Limited <i>Baron et. al.</i>	
11	3998951		1976-12-21	FMC Corporation <i>Harnish et. al.</i>	
12	4051252		1977-09-27	Bayer Aktiengesellschaft <i>Mayer et. al.</i>	
13	4493726		1985-01-15	Ciba-Geigy Corporation <i>Burdeska et. al.</i>	
14	5972946		1999-10-26	Dainippon Pharmaceutical Co., Ltd. <i>Murata et. al.</i>	
15	6093716		2000-07-25	Colltech Therapeutics, Limited <i>Davis et. al.</i>	
16	6277989	B1	2001-08-21	Scios, Inc. <i>chakravarty et. al.</i>	
17	6579983	B1	2003-06-17	Colltech R&D Limited <i>Batchelor et. al.</i>	
18	6660731	B2	2003-12-09	Vertex Pharmaceuticals Incorporated <i>Bebbington et. al.</i>	
19	6184226	B1	2001-02-06	Scios Inc. <i>chakravarty et. al.</i>	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR.1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthorn Ngo Truong
Attorney Docket Number	VPI/00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

	20	6589958	B1	2003-07-08	Bristol-Myers Squibb Pharma Company Frietze	
	21	7008948	B2	2006-03-07	Vertex Pharmaceuticals, Incorporated Bebbington et. al.	
	22	6696452	B2	2004-02-24	Vertex Pharmaceuticals Incorporated Davies et. al.	
	23	7098330	B2	2006-08-29	Vertex Pharmaceuticals Incorporated Bebbington et. al.	
Duplicate	24	6660731	B2	2003-12-09	Vertex Pharmaceuticals Incorporated	
	25	6613776	B2	2003-09-02	Vertex Pharmaceuticals Incorporated Kriegtel et. al.	
	26	6638926	B2	2003-10-28	Vertex Pharmaceuticals Incorporated Davies et. al.	
	27	6610677	B2	2003-08-26	Vertex Pharmaceuticals Incorporated Davies et. al.	
	28	7115739	B2	2006-10-03	Vertex Pharmaceuticals Incorporated Bebbington et. al.	
	29	7179826	B2	2007-02-20	Vertex Pharmaceuticals Incorporated Bebbington et. al.	
	30	6846928	B2	2005-01-25	Vertex Pharmaceuticals Incorporated Bebbington et. al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VPI/00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

31	7091343	B2	2006-08-15	Vertex Pharmaceuticals— Incorporated Bebbington et. al.	
32	4540698		1985-09-10	Mitsui Toatsu Chemicals Incorporated Ishikawa et. al.	
33	4711951		1987-12-08	Pharmacia Aktiebolag Axen et. al.	
34	5124441		1992-06-23	Pharmacia Aktiebolag Carlsson et. al.	
35	6562971	B2	2003-05-13	BASF Aktiengesellschaft Frauenkron et. al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20020065270	A1	2002-05-30	Bristol Myers Squibb Company— Moriarty et. al.	
	2	20010018436	A1	2001-08-30	Tularik Inc. Cushing et. al.	
	3	20020052386	A1	2002-05-02	Armistead et al.	
	4	20030004164	A1	2003-01-02	Bebbington et al.	

/Tamthom Truong/

02/08/2008

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10775699
Filing Date		2004-02-10
First Named Inventor	David Bebbington	
Art Unit	1624	
Examiner Name	Tamthom Ngo Truong	
Attorney Docket Number	VPI/00-130-07 DIV US	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

5	20050038023	A1	2005-02-17	Bebbington et al.	
6	20040214814	A1	2004-10-28	Bebbington et al.	
7	20030105090	A1	2003-06-05	Bebbington et al.	
8	20040157893	A1	2004-08-12	Bebbington et al.	
9	20030069239	A1	2003-04-10	Gytovia, Inc. <i>Cai et al.</i>	
10	20030069248	A1	2003-04-10	Chakravarty et al.	
11	20030087922	A1	2003-05-08	Bethiel et al.	
12	20030187002	A1	2003-10-02	Mortlock et al.	
13	20060270660	A1	2006-11-30	Charrier et al.	
14	20030064982	A1	2003-04-03	Davies et al.	
15	20040009981	A1	2004-01-15	Bebbington et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VPI/00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0136976	EP	A2	1985-04-10	Ciba-Geigy AG		<input type="checkbox"/>
	2	0012497	WO	A2	2000-03-09	Scios Inc.		<input type="checkbox"/>
	3	0144242	WO	A1	2001-06-21	Bristol-Myers Squibb Co.		<input type="checkbox"/>
	4	0247690	WO	A1	2002-06-20	Cytovia, Inc.		<input checked="" type="checkbox"/>
	5	0224667	WO	A1	2002-03-28	Merck Patent GMBH		<input type="checkbox"/>
	6	9614843	WO	A2	1996-05-23	Cor Therapeutics, Inc.		<input type="checkbox"/>
	7	9509851	WO	A1	1995-04-13	Ciba-Geigy AG		<input type="checkbox"/>
	8	9709325	WO	A1	1997-03-13	Signal Pharmaceuticals, Inc.		<input type="checkbox"/>
	9	9719065	WO	A1	1997-05-29	Celltech Therapeutics Limited		<input type="checkbox"/>

/Tamthom Truong/

02/08/2008

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VPI/00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

10	9811095	WO	A1	1998-03-19	Celltech Therapeutics Limited		<input type="checkbox"/>
11	9941253	WO	A1	1999-08-19	Tularik Inc.		<input type="checkbox"/>
12	0140215	WO	A1	2001-06-07	Pfizer Products Inc.		<input type="checkbox"/>
13	0147879	WO	A1	2001-07-05	Icos Corporation		<input type="checkbox"/>
14	0179198	WO	A1	2001-10-25	Agouron Pharmaceuticals, Inc.		<input type="checkbox"/>
15	0160816	WO	A1	2001-08-23	Amgen Inc.		<input type="checkbox"/>
16	0039101	WO	A1	2000-07-06	AstraZeneca UK Limited		<input type="checkbox"/>
17	0164655	WO	A1	2001-09-07	AstraZeneca AB		<input type="checkbox"/>
18	0413140	WO	A1	2004-02-12	Vertex Pharmaceuticals Incorporated		<input type="checkbox"/>
19	0250065	WO	A2	2002-06-27	Vertex Pharmaceuticals Incorporated		<input type="checkbox"/>
20	0250066	WO	A2	2002-06-27	Vertex Pharmaceuticals Incorporated		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10775699
Filing Date		2004-02-10
First Named Inventor	David Bebbington	
Art Unit	1624	
Examiner Name	Tamthom Ngo Truong	
Attorney Docket Number	VPI/00-130-07 DIV US	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

	21	0222601	WO	A1	2002-03-21	Vertex Pharmaceuticals Incorporation		<input type="checkbox"/>
	22	0279197	WO	A1	2002-10-10	Vertex Pharmaceuticals Incorporated		<input type="checkbox"/>
	23	0400833	WO	A1	2003-12-31	Vertex Pharmaceuticals Incorporated		<input type="checkbox"/>
	24	9208715	WO	A1	1992-05-29	Nissan Chemical Industries, Ltd.		<input type="checkbox"/>
	25	9322681	WO	A1	1993-11-11	Neurogen Corporation		<input type="checkbox"/>
	26	9515758	WO	A1	1995-06-15	Rhonepoulenc Rorer Pharmaceuticals Inc.		<input type="checkbox"/>
	27	9802434	WO	A1	1998-01-22	Glaxo Group Limited		<input type="checkbox"/>
	28	9814450	WO	A1	1998-04-09	Novartis AG		<input type="checkbox"/>
	29	9816502	WO	A1	1998-04-23	Warner-Lambert Company		<input type="checkbox"/>
	30	9947154	WO	A1	1999-09-23	Cytovia, Inc.		<input type="checkbox"/>
	31	9962518	WO	A1	1999-12-09	Cadus Pharmaceutical Corporation		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10775699
Filing Date		2004-02-10
First Named Inventor	David Bebbington	
Art Unit	1624	
Examiner Name	Tamthom Ngo Truong	
Attorney Docket Number	VPI/00-130-07 DIV US	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

32	0042029	WO	A1	2000-07-20	Warner-Lambert Company	<input type="checkbox"/>
33	0059509	WO	A1	2000-10-12	Novartis AG	<input type="checkbox"/>
34	0078757	WO	A1	2000-12-28	Shionogi Bioresearch Corp.	<input type="checkbox"/>
35	0112621	WO	A1	2001-02-22	Vertex Pharmaceuticals Incorporated	<input type="checkbox"/>
36	0139777	WO	A1	2001-06-07	OSI Pharmaceuticals, Inc.	<input type="checkbox"/>
37	0302312	EP	A2	1989-02-08	Bayer AG	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	Wiener, J.R. et al., "Decreased Src Tyrosine Kinase Activity Inhibits Malignant Human Ovarian Cancer Tumor Growth in a Nude Mouse Model," Clinical Cancer Research, 5, 2164-2170 (1999).	<input type="checkbox"/>
	2	Wamer, S.L. et al, "Targeting Aurora-2 Kinase in Cancer," Mol. Cancer Thera., 2, 589-585, 2003.	<input type="checkbox"/>
	3	Wagman, A.S. et al., "Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes," Current Pharmaceutical Design, 10, 1105-1137 (2004).	<input type="checkbox"/>

/Tamthom Truong/

02/08/2008

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VPI/00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

4	Nezu, Y. et al., "Dimethoxypyrimidines as Novel Herbicides. Part 2. Synthesis and Herbicidal Activity of Dimethoxyphenoxyphenoxyypyrimidines and Analogues," Pestic. Sci., 47: 115-124 (1996).	<input type="checkbox"/>
5	Tanaka, T.U. et al., "Evidence that the Ipl1-Sli15 (Aurora Kinase-INCENP) Complex Promotes Chromosome Bi-orientation by Altering Kinetochore-Spindle Pole Connections," Cell, 108, 317-329 (2002).	<input type="checkbox"/>
6	Staley, C.A. et al., "Decreased Tumorigenicity of a Human Colon Adenocarcinoma Cell-Line by an Antisense Expression Vector Specific for c-Src," Cell Growth & Differentiation, 8: 269-274 (1997).	<input type="checkbox"/>
7	Soriano, P. et al., "Targeted Disruption of the C-SIC PmtO-Oncogene Leads to Osteopetrosis in Mice," Cell, 64: 693-702, (1991).	<input type="checkbox"/>
8	Campbell, S.F. et al., "2,4-Diamino-6,7-dimethoxyquinazolines. 3.2-(4-Heterocyclypiperazin-1-yl) Derivatives as α 1-Adrenoceptor Antagonists and Antihypertensive Agents," J. Med. Chem., 30, 1794-1798 (1987).	<input type="checkbox"/>
9	Casanova, B. et al., "Revisión crítica de la patogenia actual de la esclerosis múltiple y futuras direcciones posibles," Rev. Neurol., 28 (9): 909-915 (1999).	<input checked="" type="checkbox"/>
10	Cline, G.W. et al., "Effects of a Novel Glycogen Synthase Kinase-3 Inhibitor on Insulin-Stimulated Glucose Metabolism in Zucker Diabetic Fatty (fa/fa) Rats," Diabetes, 51, 2903-2910 (2002).	<input type="checkbox"/>
11	Simone, J.V., "Oncology: Introduction" in Cecil Textbook in Medicine, 20th ed., Vol. 1, 1004-1010 (1996).	<input type="checkbox"/>
12	Coleman, R.A., "The Biological Evaluation of New Compounds" in Medicinal Chemistry: Principles and Practice, King, Frank D. ed, Royal Society of Chemistry, 53-66 (1994).	<input type="checkbox"/>
13	The CONDENSED CHEMICAL DICTIONARY, Sixth Edition by Arthur and Elizabeth Rose, 38 (1961).	<input type="checkbox"/>
14	Damasio, A.R., "Alzheimer's Disease and Related Dementia," in Cecil Textbook of Medicine, 20th ed., 2: 1992-1996 (1996).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VPI/00-130-07-DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

15	Rogers, E. et al., "The aurora kinase AIR-2 functions in the release of chromosome cohesion in <i>Caenorhabditis elegans</i> meiosis," J. Cell Biol., 157(2): 219-229 (2002).	<input type="checkbox"/>
16	Fisher A., "Therapeutic Strategies in Alzheimer's Disease: M1 Muscarinic Agonists," Jpn. J. Pharmacol., 84(2):101-12 (2000).	<input type="checkbox"/>
17	Frame, M.C., "Src in cancer: deregulation and consequences for cell behaviour," Biochimica et Biophysica Acta 1602, 114- 130 (2002).	<input type="checkbox"/>
18	Frampton, J.E. et al., "Pentoxifylline (Oxpentifylline) - A Review of its Therapeutic Efficacy in the Management of Peripheral Vascular and Cerebrovascular Disorder," Drugs & Aging, 7(6): 480-503 (1995).	<input type="checkbox"/>
19	Ganellin, C.R., "Past Approaches to Discovering New Drugs as Medicines" in Medicinal Chemistry, Principles and Practices. King, Frank D. ed, Royal Society of Chemistry, 189-205 (1994).	<input type="checkbox"/>
20	Hamdane, M. et al., "A Therapeutic Target in Alzheimer Neurodegeneration," J. Mol. Neurosci., 19(3): 275-87 (2002).	<input type="checkbox"/>
21	Hardt, S.E. et al., "Glycogen Synthase Kinase-3 β - A Novel Regulator of Cardiac Hypertrophy and Development," Circulation Research, 90: 1055-1063 (2002).	<input type="checkbox"/>
22	Parnell, E.W., "2-Cyano-4-nitrophenylhydrazine and 3-Amino-5-nitroindazole", J. Chem. Soc., 2363-2365 (1959).	<input type="checkbox"/>
23	Heaney, F. et al., "Pyrimidine annelated heterocycles—synthesis and cycloaddition of the first pyrimido[1,4]diazepine N-oxides," J. Chem. Soc., Perkin Trans. 1, 622-632 (2001).	<input type="checkbox"/>
24	Hendriksen, E.J. et al., "Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats," Am. J. Physiol. Endocrinol. Metab., 284: E892-E900 (2003).	<input type="checkbox"/>
25	Okafor, C.O., "Studies in the Heterocyclic Series. X. 1,3,9-Triazaphenothiazine Ring System, a New Phenothiazine Ring," J. Org. Chem., 40(19): 2753-2755 (1975).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VPI/00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

26	Jambhekar, S.S., "Biopharmaceutical Properties of Drug Substances" in Principles of Medicinal Chemistry, 4th ed., 12-24, (1995).	<input type="checkbox"/>
27	Layzer, R.B., "Section Five - Degenerative Diseases of the Nervous System" in Cecil Textbook of Medicine, 20th ed., 2: 2050-2057 (1996).	<input type="checkbox"/>
28	Lee, S.J. et al., "Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolylquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities," J. Med. Chem., 38 (18): 3547-3557 (1995).	<input type="checkbox"/>
29	Medwid, J.B. et al., "Preparation of Triazolo[1,5-c]pyrimidines as Potential Antiasthma Agents," J. Med. Chem. 33, 1230-1241 (1990).	<input type="checkbox"/>
30	Nezu, Y. et al., "Dimethoxypyrimidines as Novel Herbicides. Part 1. Synthesis and Herbicidal Activity of Dimethoxyphenoxyphenoxyypyrimidines and Analogues," Pestic. Sci., 47: 103-113 (1996).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Tamthom Truong/	Date Considered	02/08/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.